Skip to main content
. 2024 Mar 28;16(4):472. doi: 10.3390/pharmaceutics16040472

Table 3.

Results from the second heating cycle of the DSC analysis (means of n = 3, ±SD).

Plasticizer PVA 3-82 PVA 4-88
Tg
[°C]
ΔCp
[K/Jg−1]
Tm(1)
[°C]
ΔH(1)
[Jg−1]
Tm(2)
[°C]
ΔH(2)
[Jg−1]
Tg
[°C]
ΔCp
[K/Jg−1]
Tm(1)
[°C]
ΔH(1)
[Jg−1]
Tm(2)
[°C]
ΔH(2)
[Jg−1]
PLX 188 66.2
(±1.5)
0.375
(±0.024)
54.6
(±0.0)
12.27
(±0.215)
158.3
(±1.0)
4.37
(±0.424)
68.0
(±0.0)
0.414
(±0.014)
55.0
(±0.1)
13.06
(±0.953)
177.3
(±0.0)
8.65
(±0.236)
PLX 407 65.0
(±0.2)
0.393
(±0.022)
54.8
(±0.2)
11.82
(±1.764)
158.78
(±1.5)
4.35
(±0.367)
68.0
(±0.3)
0.386
(±0.023)
54.6
(±0.1)
11.34
(±0.520)
178.68
(±0.0)
8.79
(±0.191)
PEG 400 N/A N/A N/A N/A N/A N/A 53.9
(±0.3)
0.617
(±0.020)
N/A N/A 176.5
(±1.0)
8.40
(±0.446)
PEG 600 51.9
(±0.6)
0.813
(±0.069)
N/A N/A 173.2
(±2.7)
3.43
(±0.719)
60.9
(±0.3)
0.488
(±0.031)
19.3
(±0.1)
1.13
(±0.225)
175.6
(±0.6)
9.11
(±0.284)
PEG 1000 55.7
(±1.7)
0.490
(±0.058)
37.7
(±0.3)
0.65
(±0.093)
169.0
(±2.2)
3.87
(±0.823)
65.5
(±0.5)
0.557
(±0.071)
37.3
(±0.0)
6.26
(±1.927)
173.5
(±0.4)
10.3
(±0.277)